je.st
news
Tag: merck
Merck Foundation Grant Expands Project ECHO in Vietnam and India
2017-01-18 15:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Project Increases Access to Specialty Care for Complex, Chronic Conditions KENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation (Foundation) and the Extension for Community Healthcare Outcomes (ECHO) Institute at the University of New Mexico Health Sciences Center announced today that the Foundation has provided a grant of $7 million over five years to support the expansion of Project ECHO to improve access to specialty care for complex, chronic conditions, such as: hepatitis C, HIV, tuberculosis, and non-communicable diseases, including diabetes and mental health conditions, in underserved communities in India Language: English Contact: Merck Media Contacts:Claire Gillespie, 267-305-0932Jeanine Clemente, 908-236-5059orProject ECHO Media Contact:Andrea Bradford, 505-272-5513 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: project
india
foundation
grant
Merck Receives FDA Acceptance of Supplemental Biologics License Application for KEYTRUDA (pembrolizumab) in Combination with Chemotherapy for First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
2017-01-10 22:06:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Submission Based on Data from KEYNOTE-021 Trial, Cohort G, Which Enrolled Patients Regardless of PD-L1 Expression KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestor:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: application
license
cell
treatment
Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA (pembrolizumab)
2017-01-09 14:00:47| Merck.com - Product News
Dateline City: WILMINGTON, D.E. & KENILWORTH, N.J. Additional pivotal studies evaluating Incytes IDO1 inhibitor in combination with Mercks anti-PD-1 therapy in patients with non-small cell lung, renal, bladder and head and neck cancers expected to start in 2017 WILMINGTON, D.E. & KENILWORTH, N.J. Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical development program investigating the combination of epacadostat, Incytes investigational oral selective IDO1 inhibitor, with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy. Language: English read more
Tags: with
development
program
combination
Merck to Participate at the 35th Annual J.P. Morgan Healthcare Conference
2017-01-06 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories, are scheduled to participate at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 9, 2017 at 4:00 p.m. PST (7:00 p.m. EST). Language: English Contact: Media:Lainie Keller, 908-236-5036orClaire Gillespie, 267-305-0932orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: annual
conference
participate
morgan
Merck to Hold Fourth-Quarter and Full-Year 2016 Sales and Earnings Conference Call on February 2
2017-01-03 12:45:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2016 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Thursday, Feb. 2. During the call, company executives will provide an overview of Mercks performance for the quarter and year. Language: English Contact: MerckMedia:Lainie Keller, (908) 236-5036Claire Gillespie, (267) 305-0932orInvestor:Teri Loxam, (908) 740-1986Amy Klug, (908) 740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] next »